Skip to main navigation Skip to search Skip to main content

Chronic exposure to incretin metabolites GLP-1(9-36) and GIP(3-42) affect islet morphology and beta cell health in high fat fed mice

Research output: Contribution to journalArticlepeer-review

155 Downloads (Pure)

Abstract

The incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are rapidly degraded by dipeptidyl peptidase-4 (DPP-4) to their major circulating metabolites GLP-1(9−36) and GIP(3−42). This study investigates the possible effects of these metabolites, and the equivalent exendin molecule Ex(9−39), on pancreatic islet morphology and constituent alpha and beta cells in high-fat diet (HFD) fed mice. Male Swiss TO-mice (6–8 weeks-old) were maintained on a HFD or normal diet (ND) for 4 months and then received twice-daily subcutaneous injections of GLP-1(9−36), GIP(3−42), Ex(9−39) (25 nmol/kg bw) or saline vehicle (0.9% (w/v) NaCl) over a 60-day period. Metabolic parameters were monitored and excised pancreatic tissues were used for immunohistochemical analysis. Body weight and assessed metabolic indices were not changed by peptide administration. GLP-1(9−36) significantly (p<0.001) increased islet density per mm 2 tissue, that was decreased (p<0.05) by HFD. Islet, beta and alpha cell areas were increased (p<0.01) following HFD and subsequently reduced (p<0.01-p<0.001) by GIP(3−42) and Ex(9−39) treatment. While GLP-1(9−36) did not affect islet and beta cell areas in HFD mice, it significantly (p<0.01) decreased alpha cell area. Compared to ND and HFD mice, GIP(3−42) treatment significantly (p<0.05) increased beta cell proliferation. Whilst HFD increased (p<0.001) beta cell apoptosis, this was reduced (p<0.01-p<0.001) by both GLP-1(9−36) and GIP(3−42). These data indicate that the major circulating forms of GLP-1 and GIP, namely GLP-1(9−36) and GIP(3−42) previously considered largely inactive, may directly impact pancreatic morphology, with an important protective effect on beta cell health under conditions of beta cell stress.

Original languageEnglish
Article number171254
Pages (from-to)1-8
Number of pages8
JournalPeptides
Volume178
Early online date28 May 2024
DOIs
Publication statusPublished (in print/issue) - 31 Aug 2024

Bibliographical note

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Data Availability Statement

Data will be made available on request.

Funding

These studies were supported by Diabetes UK RD Lawrence Fellowship grant to RCM and Ulster University strategic funding.

Funders
Diabetes UK

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Islets
    • Incretin
    • GIP(3−42)
    • GLP-1(9−36)
    • Peptide Fragments/pharmacology
    • Glucagon-Like Peptide 1/metabolism
    • Gastric Inhibitory Polypeptide/pharmacology
    • Apoptosis/drug effects
    • Male
    • Diet, High-Fat/adverse effects
    • Incretins/pharmacology
    • Islets of Langerhans/drug effects
    • Insulin-Secreting Cells/drug effects
    • Animals
    • Insulin/metabolism
    • Mice

    Fingerprint

    Dive into the research topics of 'Chronic exposure to incretin metabolites GLP-1(9-36) and GIP(3-42) affect islet morphology and beta cell health in high fat fed mice'. Together they form a unique fingerprint.

    Cite this